Skip to main content
DNTH
NASDAQ Life Sciences

菊花治疗公司启动40亿美元公开募股，随着第三阶段试验结果呈现积极趋势

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$75.26
Mkt Cap
$3.425B
52W Low
$13.365
52W High
$84.86
Market data snapshot near publication time

summarizeSummary

菊花治疗公司已经启动了一项拟议的4亿美元的承销公开募股，包括普通股和/或预付担保权证。这一重大资本增加还包括承销商购买额外6,000万美元的选项，随着公司早些时候宣布其第三阶段CAPTIVATE试验中关于CIDP的克拉西布的早期“GO决定”。虽然这一公开募股为临床和临床前开发以及商业准备提供了大量资金，但也意味着现有股东将遭受重大稀释。该公司正在战略性地利用积极的临床动力来加强其资产负债表。交易者将关注最终条款和市场对这一稀释性融资的反应。

在该公告发布时，DNTH的交易价格为$75.26，交易所为NASDAQ，所属行业为Life Sciences，市值约为$34.2亿。 52周交易区间为$13.37至$84.86。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed DNTH - Latest Insights

DNTH
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Secures $676M in Offering, Receives Favorable FDA Feedback for Claseprubart Trials
Sentiment: Positive
View Wiseek Article
DNTH
Mar 13, 2026, 8:40 PM EDT
Source: Wiseek News
Importance Score:
8
Dianthus CEO, Key Executives Liquidate All Direct Stock Holdings
Sentiment: Negative
View Wiseek Article
DNTH
Mar 12, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Finalizes $673.5M Upsized Public Offering, Including Full Underwriter Option Exercise
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 11, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Dianthus Therapeutics Prices $625M Public Offering at $81.00 Per Share, Extending Cash Runway
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 10, 2026, 10:56 PM EDT
Source: Reuters
Importance Score:
8
Dianthus Therapeutics Prices Upsized $625M Offering at $81/Share
Sentiment: Negative
View Wiseek Article
DNTH
Mar 10, 2026, 9:54 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Dianthus Therapeutics Upsizes Shelf Registration by $120M, Increasing Capital Raise Capacity to $720M
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
9
Dianthus Therapeutics Details Proposed $400M Public Offering Following Positive Phase 3 Trial Results
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dianthus Therapeutics Commences $400M Public Offering Following Positive Phase 3 Trial News
Sentiment: Negative
View Wiseek Article
DNTH
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
Dianthus Therapeutics Reports Early Phase 3 Success for Claseprubart in CIDP, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
DNTH
Mar 09, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Dianthus Therapeutics Achieves Early GO Decision in Pivotal Phase 3 CIDP Trial for Claseprubart
Sentiment: Positive
View Wiseek Article